ArticlebioRxiv : the preprint server for biology2025
Transcriptional Readthrough at
Zengming Zhang, Tongbin Wu, Zeyu Chen, Danni Chen, Zhengyu Liang, Christopher Adams, Yu Gu, Mao Ye, Fhujjen Barroga, Sylvia Evans and 2 more
Abstract readPreprint
In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
12 authors.
Zengming ZhangDepartment of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Tongbin WuDepartment of Biological Sciences and Translational Medicine, Masonic Medical Research Institute, 2150 Bleecker Street, Utica, NY 13501, USA.ORCID 0000-0001-6232-3268 Zeyu ChenDepartment of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.ORCID 0000-0003-3442-4162 Danni ChenDepartment of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Zhengyu LiangDepartment of Cellular and Molecular Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Christopher AdamsDivision of Endocrinology, Diabetes, Metabolism and Nutrition, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Yu GuDepartment of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.ORCID 0000-0002-9543-8472 Mao YeDepartment of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Fhujjen BarrogaHerbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Sylvia EvansSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, 92093, USA.ORCID 0000-0001-5035-3697 Xiaohai ZhouDepartment of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.ORCID 0000-0002-0987-0374 Ju ChenDepartment of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.ORCID 0000-0001-7674-4776 Funding
U of Calif, San Diego Neuroscience Microscopy ImagingP30NS047101 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GLEESON, JOSEPH G, ZHENG, BINHAI · 2003 to 2022
$9.0MATF4 a Novel Regulator of Cardiac DevelopmentR01HL164549 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Ju Chen · 2023 to 2026
$2.2MMolecular basis of ASNA1 cardiomyopathyR01HL170002 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Ju Chen · 2024 to 2026
$1.6MGene Therapy for ALPK3 Cardiomyopathy Using MiniALPK3R01HL175344 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Ju Chen · 2024 to 2026
$1.6MIllumina NovaSeq 6000 Sequencing SystemS10OD026929 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEPSEN, KRISTEN LYNN · 2019 to 2019
$600kNHLBI NIH HHS R01 HL164549NHLBI NIH HHS R01 HL170002NHLBI NIH HHS R01 HL175344NIH HHS S10 OD026929NINDS NIH HHS P30 NS047101
6 · The paper itselfAbstract
backgroundActivating Transcription Factor 4 (ATF4) functions as a transcriptional regulator in various cell types and tissues under both physiological and pathological conditions. While previous studies have linked ATF4 activation with promoting cardiomyocyte (CM) death in dilated cardiomyopathy (DCM), atrial fibrillation, and heart failure, its role in developing CMs remains unexplored.
methodsWe generated multiple distinct CM-specific (
results
conclusionsWe found that the downregulation of TRANSLATIONAL PERSPECTIVE: Our findings clarify ATF4's role in heart development by showing that cardiac defects in cardiomyocyte-specific ATF4 knockout mice-using a widely employed floxed ATF4 line-result from unintended downregulation of RPS19BP1 caused by transcriptional readthrough. This shifts the focus from ATF4 to RPS19BP1, a key regulator of p53 activity, as a potential driver of cardiac developmental abnormalities. Clinically, these insights caution against misinterpretation of genetic knockout models and highlight RPS19BP1 as a promising target for congenital heart disease and related cardiac dysfunctions, with potential implications for future therapies.
Identifiers
PMID40909608
PMCPMC12407945
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390